Effect of COPD severity on hemodynamic responses to exercise in patients with GOLD stages I-IV Source: Annual Congress 2011 - Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation Year: 2011
The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012
Responses to polymeric lung volume reduction (PLVR) therapy at 6 months in patients with GOLD stage III emphysema Source: Annual Congress 2010 - Interventions for obstructive lung diseases Year: 2010
Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III Source: Eur Respir J 2006; 28: 939-944 Year: 2006
Comorbidities in stage IV COPD patients Source: Annual Congress 2011 - COPD management Year: 2011
Ventilation-perfusion imbalance and GOLD stages in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 407s Year: 2006
Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPDÔ trial Source: Annual Congress 2011 - COPD management Year: 2011
Effect of olodaterol once-daily on heart rate in GOLD 2–4 COPD patients Source: International Congress 2017 – COPD management Year: 2017
Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Combining physical activity monitoring and cardiac output during exercise in COPD patients with GOLD stages II-IV Source: Annual Congress 2011 - Skeletal muscle weakness in COPD: physical (in)activity and biological markers Year: 2011
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014
Effects of respiratory muscle training and cycle ergometry training in patients with severe COPD (GOLD IV) Source: Eur Respir J 2004; 24: Suppl. 48, 517s Year: 2004
Impact of symptomatology in patients with GOLD stage I COPD Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010
The lung deposition of tiotropium in COPD patients is comparable to that in healthy subjects and independent of the stage of COPD disease Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003
Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010
GOLD stage 0 and risk of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 352s Year: 2003
Use of quality of life measures and FEF25-75 to stratify GOLD stage I COPD into stage IA and stage IB Source: Eur Respir J 2002; 20: Suppl. 38, 122s Year: 2002
Hyperinflation in GOLD 2 COPD Source: Eur Respir J 2006; 28: Suppl. 50, 806s Year: 2006
Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015